Cepharanthine has been shown to significantly inhibit SARS-CoV-2 viral entry by binding to and blocking viral spike protein engagement with its human cell surface docking site, the angiotensin converting enzyme 2 (ACE2)
Sairiyo is currently pursuing FDA clinical trials for mild-to-moderate COVID- 19 infection.
With US patent protection until 2036, Sairiyo is developing PD-001 as a potential oral medication to be taken at home to diminish the likelihood of worsening symptoms following Covid-19 diagnosis.
Sairiyo holds exclusive rights to all fields of use for a novel, high oral bioavailability (~70%) formulation of cepharanthine, PD-001.
Sairiyo looks to bring PD-001 to individuals infected with Covid-19 by leveraging the “Whole-of-Government Effort’ currently initiated by the U.S. government aimed at developing oral antiviral drugs for home use.
